Genome Medicine (Jul 2022)

X-CAP improves pathogenicity prediction of stopgain variants

  • Ruchir Rastogi,
  • Peter D. Stenson,
  • David N. Cooper,
  • Gill Bejerano

DOI
https://doi.org/10.1186/s13073-022-01078-y
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Stopgain substitutions are the third-largest class of monogenic human disease mutations and often examined first in patient exomes. Existing computational stopgain pathogenicity predictors, however, exhibit poor performance at the high sensitivity required for clinical use. Here, we introduce a new classifier, termed X-CAP, which uses a novel training methodology and unique feature set to improve the AUROC by 18% and decrease the false-positive rate 4-fold on large variant databases. In patient exomes, X-CAP prioritizes causal stopgains better than existing methods do, further illustrating its clinical utility. X-CAP is available at https://github.com/bejerano-lab/X-CAP .

Keywords